Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
AssigneeHolobiome, Inc.
InventorsStephen SKOLNICK, Philip STRANDWITZ
Life of this patent
Estimating the term…
Abstract
The technology described herein is directed to compositions and methods for treating CNS diseases or disorders associated with microbiome dysbiosis. In one aspect, described herein are compositions and methods for treating CNS diseases or disorders associated with a microbiome deficient in queuine biosynthesis. In another aspect, described herein are compositions and methods for treating CNS diseases or disorders associated with a microbiome deficient in endozepine biosynthesis. In another aspect, described herein are compositions and methods for treating CNS diseases or disorders associated with a microbiome deficient in heavy metal sequestration.
Claims24
A composition comprising one or more isolated, non-pathogenic queuine-producing bacterial strains or an isolated product derived therefrom, wherein the one or more isolated, non-pathogenic queuine-producing bacterial strains comprise live bacteria or dead bacteria, or wherein the isolated product derived therefrom comprises culture medium in which said one or more isolated, non-pathogenic bacterial strains have been cultured.
(canceled)
A pharmaceutical composition comprising queuine, an analog, derivative or precursor thereof, or a combination of any of these, in an amount effective to alter queuine levels in a subject in need thereof, and a pharmaceutically acceptable carrier.
(canceled)
-47. (canceled)
A composition comprising one or more isolated non-pathogenic endozepine-producing bacterial or yeast strains or an isolated product derived therefrom.
-108. (canceled)
Dependencies are inferred from the claim text.